COMBINED BRACHYTHERAPY AND HYPERTHERMIA

本提案的目的是回答这个问题，" 使用低剂量率近距离放射治疗和优于低剂量的上级热疗 单独进行近距离放射治疗". 如果是这样， 联合收割机加热和近距离放射治疗 由于细胞培养研究的组合热和低剂量率irra- 放射已经产生了重要的放射生物学线索，在体内肿瘤， 需要对正常组织进行研究，以解决一些具体问题 与临床应用有关。 为实现《行动纲领》的总体目标， study. 它们是：（i）将产生的最佳辐射剂量率 最大热辐射增敏，（ii）最佳温度和 热处理的持续时间，（iii）加热的顺序和时间， 辐射，和（iv）的关键正常组织的影响，从 结合了热量和辐射。 我们计划使用两种肿瘤系统：RIF 在C3H小鼠和9L小鼠的肌内部位生长的纤维肉瘤 费希尔大鼠脑内生长的胶质肉瘤 Ana的终点 用于肿瘤的裂解包括：（i）克隆形成测定，（ii）肿瘤生长 延迟，和（iii）肿瘤治愈率。 正常组织的终点 包括半定量皮肤评分和 纸巾 根据上述终点，定量估计 的热增强比和治疗增益。 这项研究的意义有两个方面： 放射生物学因素，可能提高治疗率的 热疗与低剂量率放射治疗联合应用 治疗抗辐射人类肿瘤的发现，包括 脑恶性胶质瘤和软组织肉瘤。

The objective of this proposal is to answer the question, "Is combined use of low dose rate brachytherapy and hyperthermia superior to low dose rate brachytherapy alone?". If so, what would be the optimum means to combine heat and brachytherapy? Since cell culture studies of the combined heat and low dose rate irra- diation have yielded important radiobiological clues, in vivo tumor and normal tissue studies are needed to address a number of specific issues relevant to clinical applications. There are four specific aims to achieve the overall objective of the study. They are: (i) an optimum radiation dose rate that would yield the maximum heat radiosensitization, (ii) an optimum temperature and duration of heat treatment, (iii) sequence and timing of heat and radiation, and (iv) the effects of critical normal tissues from the combined heat and radiation. We plan to use two tumor systems: RIF fibrosarcoma growing in the intramuscular site of C3H mice and 9L gliosarcoma growing in the brain of Fischer rats. The end points of ana- lysis for tumors include: (i) clonogenic assays, (ii) tumor growth delays, and (iii) tumor cure rates. The end points for normal tissues include semiquantitative skin scorings and histopathological changes of the tissues. Based on the foregoing end points, a quantitative estimate of thermal enhancement ratio and therapeutic gain will be made. The significance of the study would be two-fold: identification of radiobiological factors that might improve the therapeutic ratio of the combined hyperthermia and low dose rate radiotherapy, and application of the findings to the treatment of radioresistant human tumors, including malignant gliomas of the brain and soft tissue sarcomas.